Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133591) titled 'Efficacy and Safety of Trastuzumab rezetecan(SHR-A1811) in HER2-Abnormal Solid Tumors: A National Multi-Center Real-World Study' on Sept. 29.

Study Type: Observational study

Study Design: Cohort study

Primary Sponsor: Cancer Hospital Chinese Academy of Medical Sciences

Condition: Histologically/cytologically confirmed advanced/metastatic solid tumor

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-09-30

Target Sample Size: Trastuzumab Rezetecan Treatment Group:2000;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=345752

Publ...